Chrzanowska Alicja, Graboń Wojciech, Mielczarek-Puta Magdalena, Barańczyk-Kuźma Anna
Chair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Banacha 1, Poland.
Chair and Department of Biochemistry, Medical University of Warsaw, 02-097 Warsaw, Banacha 1, Poland.
Clin Biochem. 2014 Aug;47(12):1056-9. doi: 10.1016/j.clinbiochem.2014.03.019. Epub 2014 Apr 5.
To assess the utility of arginase activity and expression in diagnosis of liver diseases.
Arginase activity, sensitivity and specificity were determined in serum of 140 patients including 50 with HCC, 60 with LC, 30 with choledocholithiasis (CDL) and 90 healthy controls. In HCC and LC arginase activity in serum was studied before and after tumor resection or liver transplantation. Arginase sensitivity in HCC was compared to that of alpha-fetoprotein (AFP) and aminotransferases (AST, ALT). In LC the activity was determined also in bile before and after transplantation. The expression of arginase isoenzymes in serum was studied by Western blotting.
In HCC and LC the preoperative arginase activity was significantly higher compared to controls, and it decreased after surgery. The sensitivity of arginase in HCC was much higher than that of AFP, AST and ALT (96, 40, 20 and 18%, respectively). In HCC it was higher than in LC (93%) and CDL (33%). The specificity of arginase was above 80%. In bile of cirrhotic patients the highest activity was immediately after liver transplantation. It decreased with time but increased dramatically at the time of the graft rejection. Arginase AII was present in serum of HCC and LC but not the control cases.
The increase of arginase activity in serum accompanied by the presence of isoenzyme AII can be useful in HCC and LC diagnosis. The determination of arginase activity in bile may be helpful in monitoring liver graft recipients.
评估精氨酸酶活性及表达在肝脏疾病诊断中的效用。
测定了140例患者血清中的精氨酸酶活性、敏感性和特异性，其中包括50例肝癌患者、60例肝硬化患者、30例胆总管结石患者（CDL）以及90例健康对照者。对肝癌和肝硬化患者在肿瘤切除或肝移植前后的血清精氨酸酶活性进行了研究。将肝癌患者中精氨酸酶的敏感性与甲胎蛋白（AFP）及转氨酶（AST、ALT）的敏感性进行了比较。对肝硬化患者在移植前后胆汁中的精氨酸酶活性也进行了测定。通过蛋白质印迹法研究了血清中精氨酸酶同工酶的表达。
肝癌和肝硬化患者术前的精氨酸酶活性显著高于对照组，术后降低。肝癌患者中精氨酸酶的敏感性远高于AFP、AST和ALT（分别为96%、40%、20%和18%）。在肝癌患者中其敏感性高于肝硬化患者（93%）和胆总管结石患者（33%）。精氨酸酶的特异性高于80%。肝硬化患者胆汁中的活性在肝移植后即刻最高。其随时间降低，但在移植物排斥时急剧升高。精氨酸酶AII存在于肝癌和肝硬化患者的血清中，但对照组病例中不存在。
血清中精氨酸酶活性增加并伴有同工酶AII的存在，可用于肝癌和肝硬化的诊断。测定胆汁中的精氨酸酶活性可能有助于监测肝移植受者。
